

Group VI, claim(s) 15, drawn to a method of eliciting a somatostatin receptor effect

Group VII, claim(s) 17 and 19, drawn to a method of inhibiting the proliferation of *Helicobacter pylori*.

ELECTION

Applicants elect the invention of Group I, claims 1-7 and 11-14 drawn to compounds selected from SEQ ID NO:1-10 and those of claim 11.

The Examiner further requests an election of species.

Applicants elect the following species for consideration at this time. For claims 1-7, Applicants elect the species of SEQ ID NO:1 ((4-amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂) and the cytotoxic agent of doxorubicin. Claims 1-7 read on the elected species. For claim 11, Applicants elect the species of ((4-amino)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH₂). Claims 11-14 read on the elected species.

Applicants reserve the right to rejoin the non-elected method claims upon allowance of a composition claim. Applicants further reserve the right to rejoin non-elected species.

The Director is authorized to charge any required fee or credit any overpayment to Deposit Account Number 50-4586, please reference the attorney docket number above.

The Examiner is invited to contact the undersigned at the below-listed telephone number, if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,

GAVRILOVICH, DODD & LINDSEY LLP

Date: May 28, 2010

By: /Joseph R. Baker, Jr./

Joseph R. Baker, Jr.

Registration No. 40900

4660 La Jolla Village Drive, Suite 750
San Diego, California 92122
(858) 458-3607 (Main)
(858) 458-9986 (Fax)